Korean Circ J.  2019 Dec;49(12):1183-1195. 10.4070/kcj.2019.0180.

Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure

• Oh CM
• Cho S
• Jang JY
• Kim H
• Chun S
• Choi M
• Park S
• Ko YG

• KMID: 2464299
• DOI: http://doi.org/10.4070/kcj.2019.0180

Abstract

BACKGROUND AND OBJECTIVES
Recent studies have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure (HF)-associated hospitalization and mortality in patients with diabetes. However, it is not clear whether SGLT2 inhibitors have a cardiovascular benefit in patients without diabetes. We aimed to determine whether empagliflozin (EMPA), an SGLT2 inhibitor, has a protective role in HF without diabetes.
METHODS
Cardiomyopathy was induced in C57BL/6J mice using intraperitoneal injection of doxorubicin (Dox). Mice with HF were fed a normal chow diet (NCD) or an NCD containing 0.03% EMPA. Then we analyzed their phenotypes and performed in vitro experiments to reveal underlying mechanisms of the EMPA's effects.
RESULTS
Mice fed NCD with EMPA showed improved heart function and reduced fibrosis. In vitro studies showed similar results. Phloridzin, a non-specific SGLT inhibitor, did not show any protective effect against Dox toxicity in H9C2 cells. SGLT2 inhibitor can cause increase in blood ketone levels. Beta hydroxybutyrate (βOHB), which is well known ketone body associated with SGLT2 inhibitor, showed a protective effect against Dox in H9C2 cells and in Dox-treated mice. These results suggest elevating βOHB might be a convincing mechanism for the protective effects of SGLT2 inhibitor.
CONCLUSIONS
SGLT2 inhibitors have a protective effect in Dox-induced HF in mice. This implied that SGLT2 inhibitor therapy could be a good treatment strategy even in HF patients without diabetes.

Keyword

Heart failure; Doxycycline; Sodium-Glucose Transporter 2 Inhibitors

MeSH Terms

3-Hydroxybutyric Acid
Animals
Cardiomyopathies
Diet
Doxorubicin
Doxycycline
Fibrosis
Heart Failure*
Heart*
Hospitalization
Humans
In Vitro Techniques
Injections, Intraperitoneal
Mice
Mortality
Phenotype
Phlorhizin
3-Hydroxybutyric Acid
Doxorubicin
Doxycycline
Phlorhizin

Figure

• 

  Figure 1 The SGLT2 inhibitor protects against Dox-induced cardiac toxicity. (A) Representative images of Dox-mediated changes in cardiac structure and function from cardiac MRI. (B) and (C) The Dox+EMPA group showed reduced LV mass, decreased LVESD, and improved FS compared with the Dox group. (D) Masson's trichrome stained cross-sections of mice, 2 weeks after single Dox injection. (E) Representative images of LV sections stained with H&E and with Masson's trichrome. The Dox+EMPA group showed less myocardial damage. (F) Quantification of interstitial fibrosis. Scale bar=50 μm. Each bar represents mean±standard error of mean. Dox = doxorubicin; EF = ejection fraction; EMPA = empagliflozin; FS = fractional shortening; H&E = hematoxylin and eosin; LV = left ventricle; LVEDD = left ventricular end diastolic diameter; LVESD = left ventricular end systolic diameter; MRI = magnetic resonance imaging; SGLT2 = sodium-glucose co-transporter 2. *p<0.05.

• 

  Figure 2 The SGLT inhibitor protects cardiomyocytes by increasing βOHB. (A) and (B) Sglt1 and Sglt2 mRNA expression in mouse LV and kidney by qRT-PCR. (C) Representative light microscopic images of H9C2 cells. H9C2 cells were stimulated with 5 μM Dox or pre-treated with PHL or βOHB for 2 hours and then treated with 5 μM Dox for 24 hours. (D) H9C2 cell viability of the PHL pre-treatment group by an MTT assay. (E) H9C2 cell viability of the βOHB pre-treatment group by an MTT assay. βOHB group showed improved cell viability under 1 μM Dox-induced cardiotoxicity compared to non-treated group. Scale bar=50 μm. Each bar represents mean±standard error of mean. βOHB = beta hydroxybutyrate; Dox = doxorubicin; LV = left ventricle; mRNA = messenger RNA; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PHL = phloridzin; qRT-PCR = quantitative real-time reverse transcription polymerase chain reaction; SGLT = sodium-glucose co-transporter. *p<0.05 vs. Dox-treated group.

• 

  Figure 3 βOHB reduces ROS and improves mitochondrial function. (A) Representative confocal fluorescence images of H9C2 cells after Dox treatment. Higher level of ROS was detected by H2DCFDA staining (green fluorescence). (B) Quantification of intracellular ROS levels. βOHB reduced ROS of H9C2 cells with Dox. (C) Representative images of western blotting of cleaved caspase 3 and CHOP. (D) Densitometry analysis of immunoreactive bands of cleaved caspase 3. βOHB reduced cleaved caspase 3 expression of H9C2 cells with Dox. (E) Intracellular ATP was measured using a firefly-based ATP assay kit. Calculated ATP contents were normalized to the total protein content. Data are shown relative to ATP levels of the control (non-treated H9C2 cells). βOHB (1mM) increased ATP production compared to control. (F) Representative confocal fluorescence images of H9C2 cells stained with TMRM fluorescence probe (red fluorescence). (G) Quantification of TMRM fluorescence. βOHB restored TMRM intensity of H9C2 cells with Dox. Scale bar=50 μm. Each bar represents mean±standard error of mean. ATP = adenosine triphosphate; βOHB = beta hydroxybutyrate; CHOP = C/EBP homologous protein; DCF = 2′,7′-dichlorofluorescin; Dox = doxorubicin; H2DCFDA = 2′,7′-dichlorodihydrofluorescein diacetate; ROS = reactive oxygen species; TMRM = tetramethylrhodamine methyl ester. *p<0.05; †p<0.01.

• 

  Figure 4 The SGLT2 inhibitor protects the heart by increasing βOHB. (A) Serum βOHB levels of mice, 2 weeks after single Dox (15 mg/kg) or saline injection. EMPA increased Serum βOHB levels of mice in both Control and Dox treated mice. (B) mRNA expression of FoxO3a, Sod2, and Cat (encoding catalase) in LV tissues of mice after single Dox or saline injection. EMPA increased these genes expression in LV tissues of mice with Dox. (C) Representative images of LV sections stained with H&E and with Masson's trichrome. Mice were injected daily with βOHB intraperitoneally after single Dox injection for 14 days. (D) Gross anatomical changes of Dox-treated hearts in a chronic model. (E) Representative images of LV sections stained with H&E and with Masson's trichrome. (F) A proposed model for the cardioprotective effect of the SGLT2 inhibitor against Dox-induced HF. Heart image was obtained and modified from Pixabay 2017 (https://pixabay.com/en/heart-human-heart-anatomy-medicine-2028154). Scale bar=50 μm. Each bar represents mean±standard error of mean. βOHB = beta hydroxybutyrate; Dox = doxorubicin; EMPA = empagliflozin; H&E = hematoxylin and eosin; HF = heart failure; LV = left ventricle; mRNA = messenger RNA; ROS = reactive oxygen species; SGLT2 = sodium-glucose co-transporter 2. *p<0.05.

Reference

1. Berliner D, Bauersachs J. Current drug therapy in chronic heart failure: the new guidelines of the European Society of Cardiology (ESC). Korean Circ J. 2017; 47:543–554.

2. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016; 39:717–725.

3. Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care. 2015; 38:2344–2353.

4. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016; 65:1190–1195.

5. Grabacka M, Pierzchalska M, Dean M, Reiss K. Regulation of ketone body metabolism and the role of PPARα. Int J Mol Sci. 2016; 17:E2093.

6. Vettor R, Inzucchi SE, Fioretto P. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia. 2017; 60:395–398.

7. Kong G, Huang Z, Ji W, et al. The ketone metabolite β-hydroxybutyrate attenuates oxidative stress in spinal cord injury by suppression of class I histone deacetylases. J Neurotrauma. 2017; 34:2645–2655.

8. Napolitano A, Miller S, Murgatroyd PR, et al. Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. J Clin Transl Endocrinol. 2013; 1:e3–8.

9. Thapa S, Trivedi N, Omer A. Elevated serum beta-hydroxybutyrate levels (B-hb) in patients with type 2 diabetes mellitus using sodium-glucose cotransporter 2 (SGLT-2) inhibitor. Novel treatment for diabetes-focusing on GLP-1 and SGLT2 (posters). In : The 98th Annual Meeting of the Endocrine Society; 2016 Apr 1–4; Fri, USA. Boston (MA): Endocrine Society;2016.

10. Breckenridge R. Heart failure and mouse models. Dis Model Mech. 2010; 3:138–143.

11. Jin Z, Zhang J, Zhi H, et al. Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy. J Cardiol. 2013; 62:110–116.

12. Gao S, Ho D, Vatner DE, Vatner SF. Echocardiography in mice. Curr Protoc Mouse Biol. 2011; 1:71–83.

13. Lee BS, Kim SH, Jin T, et al. Protective effect of survivin in doxorubicin-induced cell death in h9c2 cardiac myocytes. Korean Circ J. 2013; 43:400–407.

14. Joshi DC, Bakowska JC. Determination of mitochondrial membrane potential and reactive oxygen species in live rat cortical neurons. J Vis Exp. 2011; 2704.

15. Mouli S, Nanayakkara G, AlAlasmari A, et al. The role of frataxin in doxorubicin-mediated cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2015; 309:H844–59.

16. Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010; 1:57–92.

17. Lopaschuk GD, Verma S. Empagliflozin's fuel hypothesis: not so soon. Cell Metab. 2016; 24:200–202.

18. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015; 38:1638–1642.

19. Guh JY, Chuang TD, Chen HC, et al. β-hydroxybutyrate-induced growth inhibition and collagen production in HK-2 cells are dependent on TGF-β and Smad3. Kidney Int. 2003; 64:2041–2051.

20. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012; 52:1213–1225.

21. Mitry MA, Edwards JG. Doxorubicin induced heart failure: phenotype and molecular mechanisms. Int J Cardiol Heart Vasc. 2016; 10:17–24.

22. Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015; 21:263–269.

23. Liu X, Wang X, Zhang X, Xie Y, Chen R, Chen H. C57BL/6 mice are more appropriate than BALB/C mice in inducing dilated cardiomyopathy with short-term doxorubicin treatment. Acta Cardiol Sin. 2012; 28:236–240.

24. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373:2117–2128.

25. Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013; 339:211–214.

26. Sampson M, Lathen DR, Dallon BW, et al. β-Hydroxybutyrate improves β-cell mitochondrial function and survival. J Insul Resist. 2017; 2:8.

27. Lim S, Chesser AS, Grima JC, et al. D-β-hydroxybutyrate is protective in mouse models of Huntington's disease. PLoS One. 2011; 6:e24620.

28. Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016; 133:698–705.

29. Yu Y, Yu Y, Zhang Y, Zhang Z, An W, Zhao X. Treatment with D-β-hydroxybutyrate protects heart from ischemia/reperfusion injury in mice. Eur J Pharmacol. 2018; 829:121–128.